The Standard of Care for PMAD Screening: ACOG, AAP, and USPSTF Guidelines
Written by
Phoenix Health Editorial Team
Expert health information, double-checked for accuracy and written to be helpful.
Last updated
Why These Guidelines Matter
Clinical guidelines from ACOG, AAP, and USPSTF are not regulations. Providers are not directly penalized for failing to follow them. Their significance is twofold: they define the evidence-based standard of care, and they define the expert standard in malpractice proceedings.
When an adverse outcome follows a missed PMAD diagnosis, the plaintiff's expert will cite ACOG, AAP, and USPSTF recommendations to establish what a reasonably competent provider in the same specialty should have done. A provider who was unaware of these recommendations is not protected by the ignorance.
Understanding the specific language and scope of each guidance also matters for practice workflow: the recommendations are more specific than "screen for depression," and getting the details right is what separates compliant from non-compliant practice.
---
ACOG Guidance
Committee Opinion 757 (Screening for Perinatal Depression)
ACOG's primary guidance document on PMAD screening recommends:
Universal screening: "All pregnant and postpartum women should be screened for depression and anxiety symptoms." This is a universal, not risk-based, recommendation. Restricting screening to patients with visible risk factors is not consistent with the guidance.
Validated tool: Screening should be performed using a validated instrument. ACOG identifies the EPDS as a validated tool. The PHQ-9 is also validated for this population. An informal clinical interview is not an equivalent substitute for a validated tool.
Screening timing: ACOG recommends screening at least once during the perinatal period. The guidance does not specify a single required timepoint, but identifies both the prenatal and postpartum periods as appropriate.
Positive screen response: ACOG specifies that a positive screen requires clinical assessment and referral to mental health services when indicated. The screen is the start of the clinical process, not the endpoint.
Additional ACOG positions
ACOG has addressed several related areas relevant to practice:
- ACOG guidance on mood disorders in pregnancy addresses antidepressant prescribing and collaborative care with psychiatry
- ACOG's guidance on care for survivors of intimate partner violence addresses co-occurring conditions (IPV and PMADs co-occur at elevated rates)
- ACOG Practice Bulletin on Postpartum Care includes mental health as a component of comprehensive postpartum care
---
AAP Guidance
Policy Statement: Identifying Infants and Young Children with Developmental Disorders (Updated Positions on PPD Screening)
The AAP's 2019 policy statement specifically addressed postpartum depression screening by pediatricians, shifting from a supportive position to an explicit recommendation:
Recommended screening timepoints: 1-, 2-, 4-, and 6-month well-child visits using the EPDS or other validated tool.
Rationale: PPD affects maternal-infant attachment, which has direct consequences for infant development. Pediatricians are positioned to identify PPD at well-child visits, particularly when the mother's OB follow-up has concluded.
Practice implication: This recommendation places a PMAD screening obligation on pediatricians, not only on obstetric providers. Pediatric practices that have not implemented systematic maternal PPD screening at well-child visits are out of alignment with AAP policy.
Positive screen response: The AAP recommendation includes providing referral resources and follow-up, not only administering the screen.
---
USPSTF Guidance
Grade B Recommendation: Screening for Depression in Adults (Including Pregnant and Postpartum Women)
The USPSTF recommendation was updated in 2016 to explicitly address pregnant and postpartum women:
Recommendation: Screening for depression in the general adult population, with explicit statement that this applies to pregnant and postpartum women.
Grade: B
Practical significance of Grade B: Under the Affordable Care Act, USPSTF Grade A and B preventive services must be covered without cost-sharing by most non-grandfathered health plans. This means perinatal depression screening is a covered preventive service for most patients with commercial insurance.
Screening tools: USPSTF does not mandate a specific tool; it recognizes multiple validated instruments including the EPDS and PHQ-9.
---
What the Guidelines Do Not Specify
Understanding the gaps in guidance is important for practice design:
Frequency: ACOG says "at least once." AAP specifies four timepoints for pediatricians. USPSTF does not specify frequency. "At least once" is not a ceiling -- providers may screen more frequently, and many clinical programs screen at each trimester prenatally and at 2, 6, and 12 weeks postpartum.
Who administers the screen: None of the major guidelines restrict screening administration to physicians. Nurses, medical assistants, and support staff can administer validated tools. The provider is responsible for the clinical response to results.
Which validated tool to use: All major guidelines endorse a validated tool without mandating a specific one. EPDS is the most widely referenced and has specific validation for perinatal populations. PHQ-9 is acceptable and is often already integrated into EHR workflows.
What the response to a positive screen must include: ACOG says assessment and referral when indicated. The guidelines do not prescribe a specific referral protocol. The clinical obligation is to have a plan and to document it.
---
Aligning Practice With the Guidelines
A practice that is aligned with ACOG, AAP, and USPSTF guidance will have:
Universal screening: Every prenatal patient screened at least once; every postpartum patient screened at the postpartum visit; screening at well-child visits for maternal PPD through 6 months.
Validated tool administration: EPDS or PHQ-9, administered and scored, with the score documented in the chart.
Documented response to every positive screen: Clinical assessment, referral, treatment, or documented watchful waiting with rationale.
Established referral pathways: A specific referral resource for mental health services, not a generic instruction to "find a therapist."
Staff trained to respond to disclosures: Patients who disclose distress outside the formal screening encounter should receive an appropriate clinical response, not only those with positive screening scores.
---
Frequently Asked Questions
Both are validated for perinatal populations. The EPDS was specifically developed and validated for postpartum depression screening; the PHQ-9 was developed for general population screening and validated for perinatal use. The EPDS is slightly more sensitive to perinatal-specific presentations (anhedonia, anxiety) and is more widely used in perinatal research. The PHQ-9 may be easier to integrate into general EHR workflows that already include it. Either is defensible for guideline compliance.
ACOG recommends screening "during the perinatal period" which includes pregnancy. USPSTF guidance applies throughout pregnancy and postpartum. The strongest clinical case for prenatal screening is that prenatal anxiety and depression are at least as prevalent as postpartum, and they are significantly underidentified in current practice.
This is an administrative workflow issue that most practices have faced. Solutions: dedicated screening fields in the OB encounter template, paper screening with scanned documentation, or nursing workflow modifications. The documentation obligation exists regardless of EHR limitations.
In most jurisdictions, the standard of care is defined by what a reasonably competent provider in the specialty would do -- not by state statute. Guidelines from major professional organizations (ACOG, AAP) are highly influential in defining that standard, in many cases more influential than the presence or absence of a state screening mandate.
Ready to take the next step?
Our PMH-C certified therapists specialize in exactly this — and most clients are seen within a week.